Photo from wikipedia
Botulinum toxin type A (BT-A) is effective in reducing focal spasticity. A few data, instead, are available on its efficacy in improving motor function and quality of life, mostly in… Click to show full abstract
Botulinum toxin type A (BT-A) is effective in reducing focal spasticity. A few data, instead, are available on its efficacy in improving motor function and quality of life, mostly in Multiple Sclerosis (MS) patients. It is also known that physiotherapy treatment is very useful for the optimization of the BT-A therapeutic result, but international guidelines are lacking. The objective of reducing MS patient disability has to go through a correct timing for BT-A and the consequent physiotherapy treatment as well as an adequate and realistic individuation of the specific target.
Journal Title: Toxicon
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!